MEDICAL DEVICES AND DIAGNOSTICS
The Medical Devices and Diagnostics (MD&D) franchises comprise the world’s largest medical technology business, with sales of $24.6 billion, an increase of approximately 3 percent operationally. Despite the economic slowdown, which led to a decline in surgical procedures and pricing pressures across the business, we achieved growth in six of our seven franchises, as well as in all regions.
Our MD&D businesses advanced a very strong pipeline, completed and integrated several acquisitions, and aggressively expanded into emerging markets. The segment maintained or improved market share in the majority of its largest product platforms, despite intense competition.
For example, the Ethicon franchise grew 8 percent operationally, based on its strong suite of surgical products, as well as recent acquisitions in new markets like aesthetics and ear, nose and throat surgery. The Ethicon Endo-Surgery franchise grew 5 percent operationally. Double-digit growth in its advanced sterilization products and energy products were major contributors. Our Vision Care franchise had operational sales growth of 4 percent based on its core ACUVUE® Brand Contact Lens and the continued launch of 1-DAY ACUVUE® TruEye™ Contact Lenses into new markets. The Ortho Clinical Diagnostics franchise grew 4 percent operationally with the continued growth of the VITROS® 3600 and 5600 analyzers.
The DePuy franchise increased operational sales by 3 percent based on the strength of its orthopaedic reconstruction, sports medicine and neurological businesses. Diabetes care increased operational sales by 2 percent with the introduction of a number of new OneTouch® products around the world. Meanwhile, sales in the Cordis franchise continued to decline due to competition in drug-eluting stents. This was partially offset by the strong growth of electrophysiology products in the Biosense Webster business, which grew nearly 20 percent operationally for the year.
